Table 1.
Baseline clinical and laboratory characteristics of the study participants.
| Baseline | Metformin | Control | P-Value |
|---|---|---|---|
| N | 40 | 40 | |
| Age (yrs.) | 63.78 ± 1.40 | 62.00 ± 1.78 | 0.437 |
| Weight (kg) | 72.84 ± 1.31 | 72.18 ± 1.61 | 0.752 |
| BMI (kg/m2) | 25.86 ± 0.38 | 25.02 ± 0.51 | 0.191 |
| HbA1c (%) | 7.72 ± 0.22 | 7.27 ± 0.16 | 0.102 |
| GA (%) | 18.83 (16.29, 21.39) | 18.9 (16.28, 23.89) | 0.889 |
| Fast C-peptide (ng/ml) | 0.95 (0.7, 1.86) | 1.28 (0.71, 2.00) | 0.973 |
| Fast insulin (pmol/l) | 13.7 (8.6, 26.05) | 11.9 (7.85, 24.1) | 0.548 |
| Insulin dose (IU/day) | 39.23 ± 2.11 | 36.40 ± 2.19 | 0.356 |
| Acarbose (%) | 11 (27.5%) | 10 (25%) | 1 |
| Insulin secretagogues (%) | 3 (7.5%) | 2 (5%) | 1 |
| DPP-4 inhibitors (%) | 4 (10%) | 2 (5%) | 0.675 |
| TZDs (%) | 1 (2.5%) | 1 (2.5%) | 1 |
| TT<12 nmol/l (%) | 9 (22.5%) | 10 (25%) | 0.785 |
| SHBG (nmol/l) | 38.07 ± 2.04 | 40.97 ± 2.88 | 0.414 |
| TT (nmol/l) | 15.91 ± 0.79 | 15.71 ± 0.88 | 0.874 |
| FT (nmol/l) | 0.24 ± 0.01 | 0.24 ± 0.01 | 0.736 |
| Bio-T (nmol/l) | 4.69 ± 0.19 | 4.64 ± 0.20 | 0.858 |
Data were presented as means ± SE or median (25th, 75th percentile). BMI, body mass index; HbA1c, glycated hemoglobin; GA, Glycated Albumin; SHBG, sex hormone binding globulin; TT, total testosterone; FT, Free testosterone; Bio-T, bioavailable testosterone;